Understanding how IDO2 affects immune responses in autoimmune diseases
Official title: Defining the cellular and molecular mechanism of IDO2 function driving autoimmune vs.protective immune responses
Funded at Lankenau Institute for Medical Research · NIH-11044418 · Data updated 2026-11-12
This study is looking at how a specific enzyme called IDO2 in immune cells might be causing problems in autoimmune diseases like arthritis, and it aims to find new ways to help people with these conditions feel better without the harsh side effects of current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lankenau Institute for Medical Research NIH-funded |
| Lab location | 1 site (Wynnewood, United States) |
| Project start | January 8, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $529,682 |
| NIH project number | 1R01AR083882-01A1 |
| Project ID | NIH-11044418 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from autoimmune diseases, particularly those with inflammatory arthritis.
✕Less likely to help
Patients with autoimmune diseases that do not involve B cell activation or those who do not respond to current treatments may not benefit from this research.
What this research studies
This research investigates the role of IDO2, an enzyme found in immune cells, in driving autoimmune responses that lead to diseases like arthritis. By using genetic and pharmacological methods in a specific model of inflammatory arthritis, the researchers aim to uncover how IDO2 contributes to the production of autoantibodies and inflammation. The study also explores a novel function of IDO2 that may influence immune cell behavior, particularly in B cells. The goal is to identify new therapeutic targets that could alleviate symptoms of autoimmune diseases without the severe side effects associated with current treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for autoimmune diseases that reduce inflammation and improve patient quality of life.
How similar studies have gone: Previous research has shown promise in targeting immune pathways for autoimmune diseases, but the specific role of IDO2 is still being explored, making this a novel investigation.
Where this research is happening
-
Lankenau Institute for Medical Research
Wynnewood, United States Active
Researchers
- Principal investigator: Mandik-Nayak, Laura — Lankenau Institute for Medical Research
- Study coordinator: Mandik-Nayak, Laura
Related research
Other NIH-funded projects on the same topics.
-
Keeping heart muscle cells connected as the heart ages
This project looks at whether strengthening the physical links between heart muscle cells can help aging hearts keep working better.
-
Mechanotransduction in Disease: Creating Mouse Models to Study Mechanical Signals
A new mouse model project aims to understand how cells sense and respond to mechanical forces and how disruptions can contribute to diseases like heart disease, asthma, and cancer.
-
New ways to trigger tissue regrowth in young and aged animals
This grant studies how to make damaged tissues regrow by triggering the body's own regenerative pathways, using a mouse model to understand how to restore jaw bone and surrounding tissues.
-
How the IDO2 protein shapes harmful and protective immune responses in autoimmune disease
This project looks at the protein IDO2 to understand how it makes immune cells cause or prevent autoimmune disease, aiming to help people with conditions like inflammatory arthritis.
-
Understanding how to regrow lost or damaged body tissues
This research explores how to encourage the body to naturally regrow its own tissues, like bone and cartilage, by activating a special pathway.
-
Understanding how cancer begins when a key cell process is disrupted
This research aims to understand how liver cancer starts when a specific cell control system, called the Rb/E2f interaction, stops working correctly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.